This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).1
The efficacy and safety of BESPONSA were evaluated in a Phase 3 clinical trial vs standard chemotherapy.1,2
Review the safety profile of BESPONSA.1
Besponsa is a 1-hour IV infusion and can conveniently be administered in the outpatient setting.1,3
Legal Category: S1A
Further information is available upon request
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0784. June 2024